Replies to post #15171 on CytoSorbents Corporation (CTSO)

[berthabluefish1]

Dr. Chan said we are positioning Cytosorb to be used with Tocilizumab in Europe first.We believe we can be used along with Tocilizumab instead of steroids.Steriods can cause damage to the Cart T cell therapy apoptosis.The Q is.Have they tried us yet.Cart T cell got approved in Aug.2018.IMO I think they have and we should hear something pretty soon.They want to get this CRS Nipped in the Bud.JMO

[HadToHavit]

Rap

Interesting thread... Why would CAR-T Pharma speak of a cartridge that can help their with little problem.... I don't think they want to verbalize that there is a "problem" unless they have to.
Unless.. they form some alliance with said solution. Even then... would the verbalize that they had a problem... or just use the filter as a SOC for Car-T therapies.
Yes... I think that is the solution to their problem. "No Problem".
Our XYZ approach includes (but not advertised) a certain blood filter that assists the therapy.

Yes we had some CRS... but have handled it nicely. Period...

So gentlemen... IF we had a problem... we don't now.

Next question …..

[BG Man]

raptorjockey-
Please see my previous post (#14364) referencing Bellicum Pharmaceuticals.
My understanding from reading the medical literature is that the use of
CAR-T therapy is far from an exact science with varying degrees of side
effects of which cytokine storm is at the extreme. Bellicum has tried to
gain better control of the process by administration of a product (rimiducid)
which to some degree controls the activation of the CAR-T cells thus elimination or reducing some of the side effects. In the very small series
outlined in the article in my previous post, there were no episodes of
cytokine storm. As progress is made in CAR-T therapy, the treatment will
most likely become more refined with better control of the process and a
reduction and/or elimination of some of the side effects. The role of
cytosorb in CAR-T therapy will depend to some degree on how well the drug
companies are able to refine the treatment and reduce the side effects.
Regarding your question as to why there seems to be a lack of interest
in cytosorb from the leaders of CAR-T research; in medicine, everything
happens slower than you anticipate.